PCA3 and Familial prostate cancer: Currently, only one lncRNA, PCA3, has been successfully translated into an FDA-approved molecular diagnostic test, namely, PCA3 ProgensaTM (Gen-Probe Inc., San Diego, CA, USA), which is primarily recommended for patients who have previously had a negative biopsy for prostate cancer (Cui et al., 2016).